Your browser doesn't support javascript.
loading
Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance.
de la Fuente, Jaime; Lui, Jacob; Lennon, Ryan J; Chatterjee, Arjun; Graham, Rondell P; Zhang, Lizhi; Kendrick, Michael L; Truty, Mark J; Cleary, Sean P; Smoot, Rory L; Nagorney, David M; Gleeson, Ferga C; Levy, Michael J; Chandrasekhara, Vinay; Pearson, Randall K; Petersen, Bret T; Vege, Santhi S; Chari, Suresh T; Majumder, Shounak.
Affiliation
  • de la Fuente J; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Lui J; Department of Internal Medicine, Columbia University Irving Medical Center and the Vagelos College of Physicians and Surgeons, New York, New York.
  • Lennon RJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester Mayo Clinic, Rochester, Minnesota.
  • Chatterjee A; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.
  • Graham RP; Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Zhang L; Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Kendrick ML; Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota.
  • Truty MJ; Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota.
  • Cleary SP; Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota.
  • Smoot RL; Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota.
  • Nagorney DM; Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota.
  • Gleeson FC; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Levy MJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Chandrasekhara V; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Pearson RK; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Petersen BT; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Vege SS; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
  • Chari ST; Department of Gastroenterology and Hepatology, University of Texas MD Anderson, Houston, Texas.
  • Majumder S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Gastro Hep Adv ; 1(6): 1099-1107, 2022.
Article in En | MEDLINE | ID: mdl-39131265
ABSTRACT
Background and

Aims:

Management of intraductal papillary mucinous neoplasms (IPMNs) relies on clinical and imaging features to select patients for either pancreatectomy or periodic image-based surveillance. We aimed to compare outcomes in patients with IPMNs who underwent surgery at diagnosis with those who underwent surgery after a period of surveillance and identify preoperative clinical and imaging features associated with advanced neoplasia.

Methods:

Patients with surgically resected IPMN (n = 450) were divided into 2 groups "immediate surgery" resection within 6 months of IPMN detection, and "surveillance surgery" resection after surveillance >6 months. Survival was analyzed with Kaplan-Meier estimates and Cox proportional hazard models.

Results:

Pancreatic cancers in the surveillance surgery group (n = 135) was more frequently stage I compared with the immediate surgery group (9/13, 69.2% vs 41/110, 37.3%; P = .027). Among Fukuoka "worrisome features," only main pancreatic duct dilation 5-9 mm (odds ratio [OR] = 3.12, 95% confidence interval [CI] 1.72-5.68; P < .001) and serum CA 19-9≥ 35 U/mL (OR = 2.82, 95% CI 1.31-6.06; P = .008) were significantly associated with advanced neoplasia. In addition, smoking history was associated with increased risk of advanced neoplasia (OR = 2.05, 95% CI 1.23-3.43). Occurrence of future cancer was 16-fold higher in IPMN with high-grade dysplasia when compared with low-grade dysplasia (hazard ratio 16.5; 95% CI 4.19-64.7).

Conclusion:

Surveillance-detected pancreatic cancers in patients with IPMNs are more frequently stage I, and IPMN-HGD on surgical pathology is associated with significant risk of future pancreatic cancer. In addition to known "high-risk" features, main pancreatic duct dilation 5-9 mm, CA 19-9 elevation, and smoking history are significantly associated with advanced neoplasia.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gastro Hep Adv Year: 2022 Document type: Article Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gastro Hep Adv Year: 2022 Document type: Article Country of publication: Netherlands